WASHINGTON — It does not seem to matter how angrily President Trump tweets, how pointedly House Speaker Nancy Pelosi lobs a critique, or how shrewdly health secretary Alex Azar drafts a regulatory change.

The pharmaceutical industry is still winning in Washington.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The idea that big scary PBMs are preventing weak little pharma companies from voluntarily lowering their drug prices is nothing more than a ripe cow pie, plain and simple. Regulations weakening PBMs will just streamline the year-over-year price hikes on meds and enable pharma to lay off some excess accounting staff.

    ““We’re getting killed!” one pharma lobbyist told STAT.”

    Oh yeah, your profits are falling soooooooooo much that you might only get a $10k bonus this Christmas. How terrrrrrible! Now excuse me while I go decant these crocodile tears into an EpiPen and mark it up 2,000% percent for Mylan.

Your daily dose of news in health and medicine

Privacy Policy